Skip to main content

Macular Edema clinical trials at UC Davis
3 research studies open to eligible people

  • A Study of Experimental Medicines Aflibercept vs. Bevacizumab for Diabetic Macular Edema (swelling in the center of the eye)

    open to eligible people ages 18 years and up

    Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss. Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

    Oakland, California and other locations

  • A Study of Experimental Treatment With Micropulse for Diabetic Macular Edema (build-up of fluid in the eye)

    “This study will test the effect of using the subthreshold micropulse diode laser (SML).”

    open to eligible people ages 18 years and up

    Diabetic retinopathy is one of the most common complications of diabetes and diabetic macular edema (DME) is one of the most common causes of vision loss in diabetes. The purpose of this study is to determine if early intervention with micropulse laser treatment in eyes with good visual acuity (20/32 or better) will improve or stabilize vision loss due to the complications of diabetic macular edema.

    Sacramento, California

  • A Study to Evaluate the Effectiveness and Safety of Experimental Faricimab (RO6867461) for Diabetic Macular Edema (YOSEMITE)

    open to eligible people ages 18 years and up

    This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

    Sacramento, California and other locations

Last updated: